Latest News

WHO plans to declare common sweetener as possible carcinogen


 

The World Health Organization is set to list the artificial sweetener aspartame as a possible carcinogen.

The move, reported by multiple media sources, is expected during a July 14 meeting of WHO research experts – the International Agency for Research on Cancer. Reuters cited two unnamed sources “with knowledge of the process,” noting that aspartame is one of the world’s most commonly used sweeteners.

Aspartame is 200 times sweeter than sugar and was first approved by the Food and Drug Administration in 1974 for use as a tabletop sweetener and in chewing gum and cold breakfast cereals, as well as instant coffee, gelatins, puddings and fillings, and dairy products. Up to 95% of carbonated soft drinks that have a sweetener use aspartame, and the substance is often added by consumers to beverages (it’s the blue packet of sweetener in the array of packets that appear on diner and restaurant tables), The Washington Post reported.

The WHO currently lists 126 agents as known to be carcinogenic to humans, ranging from alcohol and tobacco to outdoor air pollution. The WHO also lists 94 agents as “probably” carcinogenic to humans and 322 agents as “possibly” carcinogenic to humans. Aspartame would join the “possibly” group, which includes gasoline engine exhaust and working as a dry cleaner.

Earlier this year, the WHO warned that people should not use nonsugar sweeteners to control their weight because of potential health risks.

A version of this article originally appeared on WebMD.com.

Recommended Reading

Low copays drive better adherence to new diabetes drugs
Clinician Reviews
SURMOUNT-2: Tirzepatide rings up major weight loss in type 2 diabetes
Clinician Reviews
‘Striking’ benefit of lipid lowering in primary prevention
Clinician Reviews
OASIS and PIONEER PLUS support high-dose oral semaglutide
Clinician Reviews
Children with type 2 diabetes face dire complications as young adults
Clinician Reviews
SAFE algorithm detects liver disease in general population
Clinician Reviews
ADA: Screen all with type 2 diabetes for fatty liver disease
Clinician Reviews
Once-weekly basal insulin nears market for type 2 diabetes
Clinician Reviews
CGM alarm fatigue in youth?
Clinician Reviews
Tirzepatide: Therapeutic titan or costly cure?
Clinician Reviews